Related references
Note: Only part of the references are listed.Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al.
BLOOD (2011)
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype
Frederik Damm et al.
BLOOD (2011)
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
Sanne Lugthart et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities
Stefan Groeschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome
Annika Dufour et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations
Claire L. Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Bas J. Wouters et al.
BLOOD (2009)
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
T. Pabst et al.
BRITISH JOURNAL OF CANCER (2009)
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
Roel G. W. Verhaak et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Christian Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia:: a Cancer and Leukemia Group B (CALGB) study
Christian Langer et al.
BLOOD (2008)
High EVI1 levels predict adverse outcome in acute myeloid leukemia:: prevalence of EVI1 overexpression. and chromosome 3q26 abnormalities underestimated
Sanne Lugthart et al.
BLOOD (2008)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
M. E.D. Chamuleau et al.
HAEMATOLOGICA (2008)
Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
Dimitri A. Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia:: A Cancer and Leukemia Group B study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old
G. Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics
Michael Heuser et al.
BLOOD (2006)
Unbiased recursive partitioning: A conditional inference framework
Torsten Hothorn et al.
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS (2006)
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
Christian Thiede et al.
BLOOD (2006)
BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics:: Prognostic implications
CD Baldus et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype:: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):: association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
RGW Verhaak et al.
BLOOD (2005)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
S Schnittger et al.
BLOOD (2005)
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
K Döhner et al.
BLOOD (2005)
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype
G Cazzaniga et al.
BLOOD (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostically useful gene-expression profiles in acute myeloid leukemia
PJM Valk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients
GJ Ossenkoppele et al.
BLOOD (2004)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
K Ozeki et al.
BLOOD (2004)
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics:: Prognostic relevance and analysis of cooperating mutations
S Fröhling et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia
M Yanada et al.
LEUKEMIA & LYMPHOMA (2004)
Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia
M Garg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics:: a Cancer and Leukemia Group B Study
CD Baldus et al.
BLOOD (2003)
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia
B Löwenberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
RS Care et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
High EVI1 expression predicts poor survival in acute myeloid leukemia:: a study of 319 de novo AML patients
SBV van Doorn-Khosrovani et al.
BLOOD (2003)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm
S Fröhling et al.
BLOOD (2002)
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia:: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme et al.
BLOOD (2002)
Share Paper
